Table 1 Demographics
From: Impact of HIV infection on consolidative radiotherapy for non-Hodgkin diffuse large B-cell lymphoma
Patients characteristics | HIV | p | |
|---|---|---|---|
No N = 331 (92.2%) | Yes N = 28 (7.8%) | ||
Age: mean (years) | 54.4 | 39.0 | |
ECOG | |||
0 | 208 (62.8%) | 20 (71.4%) | 0.632 |
1 | 82 (24.8%) | 3 (10.7%) | |
2 or lower | 41 (12.4%) | 5 (17.9%) | |
Staging | |||
PET | 280 (84.6%) | 10 (35.7%) | < 0.005 |
CT | 51 (15.4%) | 18 (64.3%) | |
IPI | |||
Low | 40 (12.1%) | 3 (10.7%) | 0.958 |
Intermediate | 88 (26.6%) | 8 (28.6%) | |
High-Intermediate | 75 (22.7%) | 5 (17.9%) | |
High | 128 (38.6%) | 12 (42.9%) | |
Stage | |||
I | 43 (13.1%) | 4 (14.3%) | 0.986 |
II | 105 (31.7%) | 8 (28.6%) | |
III | 37 (11.2%) | 3 (10.7%) | |
IV | 145 (43.8%) | 13 (46.4%) | |
Localization | |||
Above diaphragm | 111 (33.5%) | 12 (42.9%) | 0.593 |
Below diaphragm | 76 (23.0%) | 6 (21.4%) | |
Both sides | 144 (43.5%) | 10 (35.7%) | |
Bulky disease | |||
No | 119 (36.0%) | 11 (39.3%) | 0.724 |
Yes | 212 (64.0%) | 17 (60.7%) | |
Extranodal disease | |||
No | 58 (17.5%) | 6 (21.4%) | 0.380 |
Yes | 273 (82.5%) | 22 (78.6%) | |
B Symptoms | |||
No | 116 (35.0%) | 12 (42.9%) | 0.264 |
Yes | 215 (65.0%) | 16 (57.1%) | |
Chemotherapy | |||
CHOP | 298 (90.0%) | 12 (42.9%) | < 0.005 |
Others | 32 (10.0%) | 16 (57.1%) | |
Toxicities to chemotherapy | |||
No toxicities | 7 (2.1%) | 2 (7.4%) | 0.141 |
Grade I | 41 (12.5%) | 0 | |
Grade II | 74 (22.5%) | 8 (29.6%) | |
Grade III | 114 (34.7%) | 12 (44.4%) | |
Grade IV | 91 (27.7%) | 5 (18.5%) | |
Grade V | 2 (0.6%) | 0 | |
Response to chemotherapy | |||
Complete response | 138 (41.7%) | 17 (60.7%) | 0.554 |
Partial response | 125 (37.8%) | 11 (39.3%) | |
Disease Progression | |||
No | 259 (78.2%) | 21 (75.0%) | 0.363 |
Yes | 72 (21.8%) | 7 (25.0%) | |
Death | |||
No | 252 (76.1%) | 21 (75.0%) | 0.893 |
Yes | 79 (23.9%) | 7 (25.0%) | |